100 More Jobs Cut At Infinity After AbbVie Inevitably Ends Partnership
AbbVie unsurprisingly walked away from its partnership with Infinity after disappointing Phase II results for the PI3K inhibitor duvelisib. Another 100 Infinity employees will lose their jobs as the company conserves its cash and amends its clinical trial plan.
You may also be interested in...
Copiktra (duvelisib) becomes the first dual inhibitor of PI3K delta and gamma to hit the market, placing it in competition with Gilead’s Zydelig and AbbVie’s Venclexta.
Duvelisib, licensed from Infinity in 2016, reduces risk of disease progression or death compared to Arzerra in a Phase III study in refractory CLL/SLL. Verastem hopes to file an NDA during the first half of 2018.
Private Company Edition: Scrip spoke with DDF US partner Jonathan Behr about the convergence of emerging science, venture capital investment and rising big pharma interest in neurodegeneration. Also, in recent VC financings HotSpot raised $100m, while Curie and Ablaze debuted with $75m each.